IE
TOVX icon

Israel Englander’s Theriva Biologics TOVX Stock Holding History

Israel Englander’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-537
Closed -$38K – 7508
2022
Q1 		$38K Buy
+537
New +$36.6K ﹤0.01% 6475
2018
Q3 		– Sell
-23
Closed -$48K – 4278
2018
Q2 		$48K Sell
23
-31
-57% -$71.2K ﹤0.01% 3706
2018
Q1 		$151K Sell
54
-38
-41% -$145K ﹤0.01% 3425
2017
Q4 		$410K Sell
92
-32
-26% -$200K ﹤0.01% 3193
2017
Q3 		$1.01M Sell
124
-23
-16% -$133K ﹤0.01% 2505
2017
Q2 		$729K Buy
147
+105
+250% +$523K ﹤0.01% 2614
2017
Q1 		$231K Sell
42
-44
-51% -$307K ﹤0.01% 3153
2016
Q4 		$576K Buy
+86
New +$883K ﹤0.01% 2613
2016
Q3 		– Sell
-6
Closed -$92K – 3609
2016
Q2 		$92K Sell
6
-8
-57% -$151K ﹤0.01% 3031
2016
Q1 		$285K Buy
14
+7
+100% +$105K ﹤0.01% 2792
2015
Q4 		$145K Buy
7
+4
+133% +$84.6K ﹤0.01% 3187
2015
Q3 		$65K Sell
3
-1
-25% -$24.6K ﹤0.01% 3320
2015
Q2 		$95K Sell
4
-1
-20% -$20.1K ﹤0.01% 3175
2015
Q1 		$94K Buy
+5
New +$89.3K ﹤0.01% 3412

Other funds holding TOVX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Israel Englander's TOVX Position: Q2 2022 in Review

Israel Englander sold out of Theriva Biologics (TOVX) in Q2 2022, closing a stake of 537 shares — an estimated $38K sold.

Israel Englander first reported a position in TOVX in Q1 2015 and held it in 14 quarters. The position peaked at $1.01M in Q3 2017. 30 funds tracked by Wall St. Rank hold TOVX as of Q2 2022.

  • Israel Englander reported no remaining Theriva Biologics position as of Q2 2022 after selling out during the quarter.
  • Israel Englander sold 537 Theriva Biologics shares in Q2 2022, an estimated $38K.
  • Israel Englander first reported a position in Theriva Biologics in Q1 2015 and held it in 14 quarters.
  • Israel Englander's Theriva Biologics position peaked at $1.01M in Q3 2017.
  • 30 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2022.

Based on Millennium Management's 13F filing for Q2 2022, filed 15 Aug 2022.